A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of HS-20118, and the Food Effect (FE) on the Pharmacokinetics in Adult Participants
Latest Information Update: 27 Jun 2025
At a glance
- Drugs HS 20118 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 27 Jun 2025 New trial record